This is a correction to: Daniel Gaudet, Susanne Greber-Platzer, Laurens F. Reeskamp, Gabriella Iannuzzo, Robert S. Rosenson, Samir Saheb, Claudia Stefanutti, Erik Stroes, Albert Wiegman, Traci Turner, Shazia Ali, Poulabi Banerjee, Tiera Drewery, Jennifer McGinniss, Alpana Waldron, Richard T. George, Xue-Qiao Zhao, Robert Pordy, Jian Zhao, Eric Bruckert, and Frederick J. Raal, Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy, European Heart Journal, Volume 45, Issue 27, 14 July 2024, Pages 2422–2434, https://doi.org/10.1093/eurheartj/ehae325
The originally published version of this manuscript contained the following sentence: “Recent European Society of Cardiology and European Atherosclerosis Society guidelines for patients with HoFH recommend LDL-C levels of <2.5 mmol/L (<100 mg/dL) and <1.8 mmol/L (<70 mg/dL) for adults with and without ASCVD, respectively.” This has been corrected online to: “Recent European Society of Cardiology and European Atherosclerosis Society guidelines for patients with HoFH recommend LDL-C levels of <1.8 mmol/L (<70 mg/dL) and <1.4 mmol/L (<55 mg/dL) for adults with and without ASCVD, respectively.”